- United States
- /
- Chemicals
- /
- NYSE:ECL
Is Ecolab (ECL) Undervalued Following Its 11% EPS Rise?
Ecolab (ECL) is back in focus after reporting an 11% rise in adjusted EPS, supported by 5% organic sales growth, improved pricing, and strong contributions from Life Sciences and Global High Tech.
See our latest analysis for Ecolab.
The recent earnings and ongoing share repurchases have come alongside a share price of US$279.34, with a 7.64% 90 day share price return and a 58.80% three year total shareholder return that signals sustained momentum around Ecolab’s long term story.
If Ecolab’s mix of earnings growth and capital returns has your attention, it can be a useful moment to widen your watchlist and review 19 top founder-led companies.
Ecolab’s strong recent run and richer share price invite a simple question: Is most of the upside already reflected in the stock, or does the current valuation still leave meaningful room ahead based on today’s fundamentals?
Most Popular Narrative: 14% Undervalued
Ecolab’s most followed narrative puts fair value at about $323.71 per share, comfortably above the recent $279.34 price and framing the current upside debate.
Ecolab is focusing on expanding its One Ecolab growth initiative, aiming to capitalize on market share gains and increased value pricing. This initiative is expected to drive revenue growth and improve net margins by delivering exceptional value to customers.
Analysts behind this narrative are leaning on a specific mix of revenue growth, margin expansion and a future earnings multiple that sits above the sector norm. The key question is which assumptions really carry the fair value story and how they connect to Life Sciences, digital tools and share count shrinking over time.
Result: Fair Value of $323.71 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh softer industrial demand and higher local supplier costs, which could pressure Ecolab’s margins if pricing and surcharges face resistance.
Find out about the key risks to this Ecolab narrative.
Another View: What Ecolab’s P/E Says
The fair value narrative suggests Ecolab is undervalued, yet the current P/E of 37.1x sits well above the US Chemicals industry at 25.6x and a fair ratio of 25.3x. That rich gap points to less margin for error. Which signal do you trust more?
For a closer look at how this valuation gap could close over time, and what that might mean for upside or downside risk, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Ecolab’s mix of upside potential and valuation questions raises a simple challenge for you as an investor: move quickly to review both the risks and rewards that others are watching and then weigh them against your own expectations using 1 key reward and 1 important warning sign
Looking for more investment ideas beyond Ecolab?
If Ecolab has sharpened your focus on quality and valuation, do not stop here. Broaden your opportunity set now and avoid missing other compelling setups.
- Target potential mispricings by scanning companies that screen as high quality and possibly overlooked through the 56 high quality undervalued stocks.
- Strengthen your income stream by reviewing stocks that show up as potential 8 dividend fortresses.
- Prioritise resilience by filtering for companies highlighted in the 89 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Ecolab might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NYSE:ECL
Ecolab
Provides water, hygiene, and infection prevention solutions and services in the United States and internationally.
Average dividend payer with mediocre balance sheet.
Similar Companies
Market Insights
Weekly Picks

When GPS fails: this small cap is fixing a $54B drone problem

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings
Recently Updated Narratives

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

One of the Most Mispriced Technology Ecosystems in the Market

Microsoft - A Fundamental Valuation
Popular Narratives

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
A wonderful business at reasonable price.


